Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,497.81
(
-1.65%
)
US TECH 100
23,262.40
(
-1.93%
)
Dow Jones
45,528.07
(
-1.07%
)
Brent Oil
108.36
(
3.76%
)
Bitcoin
69,860.00
(
-0.06%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 179536

Thursday, 06/19/2014 5:29:33 PM

Thursday, June 19, 2014 5:29:33 PM

Post# of 257262
Correct! DRTX’s Dalvance has non-patent Orange Book exclusivity until May 23, 2024. Dalvance was approved by the FDA on 5/23/14; it received 5 years of NCE exclusivity and an additional 5 years of ‘GAIN’ exclusivity as a novel antibiotic—10 years of exclusivity in all.

More discussion:
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/06/dalvance-gains-bonus-exclusivity-fda-grants-the-first-period-of-gain-act-exclusivity.html

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today